





LMKaplan0@gmail.com

Use of Obesity Management Medications after Metabolic / Bariatric Surgery

Lee M. Kaplan, MD, PhD

Professor of Medicine and Chief, Section of Obesity Medicine Director, Dartmouth Weight and Wellness Center Geisel School of Medicine at Dartmouth

LMKaplan0@gmail.com

5 September 2024



Fernando Botero, 1932-2023

IFSO 2024 • Melbourne, Victoria, Australia

Disclosures

I am currently or have recently been a paid consultant to the following companies and organizations:

Altimmune Kallyope

Amgen Eli Lilly & Company

AstraZeneca Neurogastrx

Bain Capital Novo Nordisk

Boehringer Ingelheim Optum Health

Cytoki Perspectum

Ethicon Pfizer

Gelesis Sidekick Health

Gilead Sciences Skye Bioscience


Glyscend twenty30.health

Intellihealth Xeno Biosciences

Johnson & Johnson Zealand





Two major challenges for metabolic/bariatric surgery






Weight loss varies widely among patients










Variable response to surgery is driven by biology





Biological approaches to suboptimal initial weight loss

- Optimize a healthy lifestyle (without recommending purposeful calorie reduction)
- Discontinue or substitute for weight gain-promoting medications
- Add a therapy with a complementary (additional) mechanism
 - Anti-obesity medication
 - Surgical conversion to a procedure with additional mechanism(s)
 - Endoscopic procedure with a complementary mechanism




Medical therapy for suboptimal weight loss or recurrent weight regain

If surgery worked mechanically (restriction or malabsorption) ...

... combination with medications would be additive at most

Since surgery works physiologically ...

... complementary mechanisms allow for synergy






Postoperative pharmacotherapy augments surgical weight loss

GRAVITAS Study

Liraglutide 1.8 mg vs. Placebo after Gastric Bypass
Patients with Type 2 Diabetes






26

Liraglutide 3.0 mg augments weight loss after metabolic surgery

BARI-OPTIMISE Trial


Subjects with suboptimal (<20%) initial weight loss after metabolic surgery

Liraglutide 3.0 mg/day vs. placebo (N=70)





Two major challenges for metabolic/bariatric surgery






Potential causes of recurrent weight gain

- Promotion of non-physiological weight loss
 - Restrictive dieting



Bariatric surgery: defense of a decreased body fat mass



Step 1:

- Obese, sham-operated controls (350 gm)
- **Thin**, chow-fed, unoperated (225 gm)
- Thin, underfed to match VSG weight (275 gm)
- **Thin**, underwent **VSG** (275 gm)

Step 2:

Calorie restrict to lose 30% body weight


Step 3:

Let them eat what they want




Effect of calorie restriction beyond physiological weight loss

STEP 1 Trial
Subjects without Diabetes
Drug Alone



STEP 3 Trial
Subjects without Diabetes
Drug Plus Calorie Reduction






Potential causes of recurrent weight gain

- Promotion of non-physiological weight loss
 - Restrictive dieting
- Progression of disease



Most recurrent weight gain is NOT from surgical or patient failure

Long-term Progression of Obesity



Time (years)




Potential causes of recurrent weight gain

- Promotion of non-physiological weight loss
 - Restrictive dieting
- Progression of disease
- Environmental factors
 - Continued exposure to obesogenic environment
 - Environmental toxins
 - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
 - Obesogenic diet
 - Obesogenic medications



Environmental influences raise the defended fat mass





Potential causes of recurrent weight gain

- Promotion of non-physiological weight loss
 - Restrictive dieting
- Progression of disease
- Environmental factors
 - Continued exposure to obesogenic environment
 - Environmental toxins
 - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
 - Obesogenic diet
 - Obesogenic medications
- Biological factors
 - Genetic predisposition?
 Not as clear as for suboptimal initial weight loss



Potential means of addressing recurrent weight gain

Cause of weight gain

Potential solution

Promotion of non-physiological weight loss (purposeful calorie restriction beyond what surgery naturally provides)

Avoid recommending purposeful calorie reduction – let the surgery do its job!

Progression of disease

Add an additional therapeutic mechanism

- Start or add an anti-obesity medication
- Convert to a different MBS operation
- Add a complementary endoscopic treatment

Environmental factors

Address the environmental factors or add an additional therapeutic mechanism

Surgical complication

Correct the surgical anatomy

Intrinsic biological or genetic factors

Add an additional therapeutic mechanism



Strategies for using medical-surgical combinations

Postoperative medical therapy

- Enhancement of suboptimal post-operative weight loss
- Rescue of recurrent post-operative weight regain
- Allows personalized approach to account for patient-to-patient variability in response to medications
- Amenable to standard sequential "trial-and-error" approach to using anti-obesity medications



Practical use of combination medical-surgical therapy

- Pharmacological treatment after completion of surgical weight loss is the most promising strategy
- Pharmacological treatment works best for suboptimal initial weight loss
 - There is also benefit for recurrent weight gain, but this use is less well studied
- Pursue a step-wise treatment strategy after surgery as you would before surgery
- Add new therapies after a stable response to previous therapies (i.e., after reaching plateau)
- There are currently no good predictors for choosing the "right" medication for an individual patient
- Drugs can be effective in combination with surgery that are ineffective alone
- Anticipate life-long use of successful approaches



For both suboptimal initial weight loss and recurrent weight gain ...

Unless there is a clear abnormality in post-operative anatomy,

Always consider adding an obesity management medication before reoperating









LMKaplan0@gmail.com

Use of Obesity Management Medications after Metabolic / Bariatric Surgery

Lee M. Kaplan, MD, PhD

Professor of Medicine and Chief, Section of Obesity Medicine Director, Dartmouth Weight and Wellness Center Geisel School of Medicine at Dartmouth

LMKaplan0@gmail.com

5 September 2024



Fernando Botero, 1932-2023

IFSO 2024 • Melbourne, Victoria, Australia